Glaukos Corp (GKOS) plunged 11.67% in the pre-market trading session on Friday, following the company's wider-than-expected net loss for the fourth quarter of 2024.
The medical technology firm reported a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss, according to data compiled by LSEG. While Glaukos posted revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors.
For the full year 2025, Glaukos forecasted sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.